{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:47:24Z","timestamp":1747223244210,"version":"3.40.5"},"reference-count":25,"publisher":"Pensoft Publishers","issue":"6","license":[{"start":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T00:00:00Z","timestamp":1703980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FM"],"abstract":"<jats:p><jats:bold>Introduction<\/jats:bold>: Coronary artery bypass surgery remains the gold standard in the treatment of patients with ischemic heart disease. However, the increased oxidative stress caused by the release of free radicals during the ischemia-reperfusion time is a well-known pathophysiological process during and after coronary revascularization procedures. It may lead to reversible and irreversible myocardial injury.<\/jats:p>\n          <jats:p>The focus of this prospective single-blinded randomized controlled trial is to investigate and analyze the effectiveness of the drug trimetazidine on reducing postoperative myocardial ischemia-reperfusion injury.<\/jats:p>\n          <jats:p><jats:bold>Aim<\/jats:bold>: We evaluated the effects of trimetazidine on reactive oxygen species that may arise from myocardial ischemia-reperfusion period or systemic inflammation after coronary artery bypass grafting (CABG) surgery.<\/jats:p>\n          <jats:p><jats:bold>Materials and methods<\/jats:bold>: The study included 90 patients divided into two groups who underwent elective coronary artery bypass surgery between March 2018 and October 2018. The patients in one of the groups received 35 mg trimetazidine twice daily as soon as they were extubated. The remainder of the pharmaceutical therapy was the same for all participants. Preoperative and postoperative levels of several blood-based biochemical markers including malondialdehyde (MDA), creatinine kinase-MB fraction (CK-MB) and high-sensitivity troponin T (hs-TnT) were measured. The data was classified and analyzed by the timing of sample collection.<\/jats:p>\n          <jats:p><jats:bold>Results<\/jats:bold>: The results indicate that postoperative trimetazidine medication reduces MDA production, resulting in reduced oxidative stress and improved cardiac cell protection via antioxidant status augmentation. The follow-up was 6 months after the surgery. The Minnesota Living with Heart Failure Questionnaire was used to assess the quality of life of patients, and the results were excellent.<\/jats:p>\n          <jats:p><jats:bold>Conclusions<\/jats:bold>: Postoperative trimetazidine therapy leads to improvement of the myocardial cell metabolism and thus reduction in post CABG ischemia-reperfusion injury.<\/jats:p>","DOI":"10.3897\/folmed.65.e102777","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T15:24:04Z","timestamp":1703863444000},"page":"915-921","source":"Crossref","is-referenced-by-count":0,"title":["The role of postoperative trimetazidine therapy in on-pump coronary artery bypass surgery"],"prefix":"10.3897","volume":"65","author":[{"given":"Kamen","family":"Stanev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Yaneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-6789","authenticated-orcid":true,"given":"Asen","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todor","family":"Gonovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2258","published-online":{"date-parts":[[2023,12,31]]},"reference":[{"key":"102777_B1","unstructured":"1. Story C, Cherney K, Nall R. The History of Heart Disease. Healthline. 2018. Available from: https:\/\/www.healthline.com\/health\/heart-disease\/history"},{"key":"102777_B2","doi-asserted-by":"crossref","unstructured":"2. Lie JT. Centenary of the first correct antemortem diagnosis of coronary thrombosis by Adam Hammer (1818-1878): English translation of the original report. Am J Cardiol 1978; 42(5):849\u201352.","DOI":"10.1016\/0002-9149(78)90106-6"},{"key":"102777_B3","unstructured":"3. Sones Jr FM, Shirey EK. Cine coronary arteriography. Mod Concepts Cardiovasc Dis 1962; 31:735\u20138."},{"key":"102777_B4","unstructured":"4. Lillehei CW, Cohen M, Warden HE, et al. The direct-vision intracardiac correction of congenital anomalies by controlled cross circulation: results in 32 patients with ventricular septal defects, tetralogy of Fallot, and atrioventricular communis defects. Surgery 1955; 38:11\u201329."},{"key":"102777_B5","doi-asserted-by":"crossref","unstructured":"5. Dennis C, Spreng DS, Nelson GE, et al. Development of a pump-oxygenator to replace the heart and lungs: an apparatus applicable to human patients and application to one case. Ann Surg 1951; 134:709\u201321.","DOI":"10.1097\/00000658-195113440-00017"},{"key":"102777_B6","unstructured":"6. Gibbon JH. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 1954; 37:171\u201385."},{"key":"102777_B7","doi-asserted-by":"crossref","unstructured":"7. Olearchyk AS. Vasilii I. Kolesov: a pioneer of coronary revascularization by internal mammary-coronary artery grafting. J Thorac Cardiovasc Surg 1988; 96(1):13\u20138.","DOI":"10.1016\/S0022-5223(19)35314-0"},{"key":"102777_B8","doi-asserted-by":"crossref","unstructured":"8. Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. Ann Thorac Surg 1968; 5(4):334\u20139.","DOI":"10.1016\/S0003-4975(10)66351-5"},{"key":"102777_B9","doi-asserted-by":"crossref","unstructured":"9. Naviaux RK. Metabolic features and regulation of the healing cycle - a new model for chronic disease pathogenesis and treatment. Mitochondrion 2019; 46:278\u201397.","DOI":"10.1016\/j.mito.2018.08.001"},{"key":"102777_B10","doi-asserted-by":"crossref","unstructured":"10. Ballinger SW, Patterson C, Knight-Lozano CA, et al. Mitochondrial integrity and function in atherogenesis. Circulation 2002; 106:544\u20139.","DOI":"10.1161\/01.CIR.0000023921.93743.89"},{"key":"102777_B11","doi-asserted-by":"crossref","unstructured":"11. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 1992; 256:628\u201332.","DOI":"10.1126\/science.1533953"},{"key":"102777_B12","doi-asserted-by":"crossref","unstructured":"12. Yu E, Calvert PA, Mercer JR, et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans. Circulation 2013; 128:702\u201312.","DOI":"10.1161\/CIRCULATIONAHA.113.002271"},{"key":"102777_B13","doi-asserted-by":"crossref","unstructured":"13. Zweier JL, Talukder MH. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006; 70(2):181\u201390.","DOI":"10.1016\/j.cardiores.2006.02.025"},{"key":"102777_B14","doi-asserted-by":"crossref","unstructured":"14. Dhalla NS, Elmoselhi AB, Hata T, et al. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res 2000; 47(3):446\u201356.","DOI":"10.1016\/S0008-6363(00)00078-X"},{"key":"102777_B15","doi-asserted-by":"crossref","unstructured":"15. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013; 123(1):92\u2013100.","DOI":"10.1172\/JCI62874"},{"key":"102777_B16","doi-asserted-by":"crossref","unstructured":"16. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998; 38(2):291\u2013300.","DOI":"10.1016\/S0008-6363(98)00033-9"},{"key":"102777_B17","doi-asserted-by":"crossref","unstructured":"17. Cameron AA, Davis KB, Rogers WJ. Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study. J Am Coll Cardiol 1995; 26(4):895\u20139.","DOI":"10.1016\/0735-1097(95)00280-4"},{"key":"102777_B18","doi-asserted-by":"crossref","unstructured":"18. Pocock SJ, Henderson RA, Seed P, et al. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation 1996; 94:135\u201342.","DOI":"10.1161\/01.CIR.94.2.135"},{"key":"102777_B19","doi-asserted-by":"crossref","unstructured":"19. Boden WE, O\u2019Rourke RA, Teo KK, et al. COURAGE trial coprincipal investigators and study coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J 2006; 151(6):1173\u20139.","DOI":"10.1016\/j.ahj.2005.08.015"},{"key":"102777_B20","doi-asserted-by":"crossref","unstructured":"20. Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38):2949\u20133003.","DOI":"10.1093\/eurheartj\/eht296"},{"key":"102777_B21","unstructured":"21. Da Silva RMFL. Additional and emerging drugs for standard therapy for patients with stable angina. E-Journal of Cardiology Practice 2017; 15(11)."},{"key":"102777_B22","unstructured":"22. Kallistratos MS, Poulimenos LE, Manolis AJ. Stable angina pectoris: which drugs or combinations to use in which patients. E-Journal of Cardiology Practice 2017; 15(8)."},{"key":"102777_B23","doi-asserted-by":"crossref","unstructured":"23. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86:580\u201388.","DOI":"10.1161\/01.RES.86.5.580"},{"key":"102777_B24","doi-asserted-by":"crossref","unstructured":"24. Di Napoli P, Chierchia S, Taccardi AA, et al. Trimetazidine improves postischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide 2007; 16:228\u201336.","DOI":"10.1016\/j.niox.2006.09.001"},{"key":"102777_B25","doi-asserted-by":"crossref","unstructured":"25. Fragasso G, Piatti PM, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003; 146(5):854.","DOI":"10.1016\/S0002-8703(03)00415-0"}],"container-title":["Folia Medica"],"original-title":[],"link":[{"URL":"https:\/\/foliamedica.bg\/article\/102777\/download\/pdf\/","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article\/102777\/download\/xml\/","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article_preview.php?id=102777&skip_redirect=1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T15:24:39Z","timestamp":1703863479000},"score":1,"resource":{"primary":{"URL":"https:\/\/foliamedica.bg\/article\/102777\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,31]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,12,31]]}},"URL":"https:\/\/doi.org\/10.3897\/folmed.65.e102777","relation":{},"ISSN":["1314-2143","0204-8043"],"issn-type":[{"type":"electronic","value":"1314-2143"},{"type":"print","value":"0204-8043"}],"subject":[],"published":{"date-parts":[[2023,12,31]]}}}